TY - JOUR
T1 - Assessment of hepatocellular carcinoma treatment response with LI-RADS
T2 - a pictorial review
AU - Voizard, Nicolas
AU - Cerny, Milena
AU - Assad, Anis
AU - Billiard, Jean Sébastien
AU - Olivié, Damien
AU - Perreault, Pierre
AU - Kielar, Ania
AU - Do, Richard K.G.
AU - Yokoo, Takeshi
AU - Sirlin, Claude B.
AU - Tang, An
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Computed tomography (CT) and magnetic resonance imaging (MRI) play critical roles for assessing treatment response of hepatocellular carcinoma (HCC) after locoregional therapy. Interpretation is challenging because posttreatment imaging findings depend on the type of treatment, magnitude of treatment response, time interval after treatment, and other factors. To help radiologists interpret and report treatment response in a clear, simple, and standardized manner, the Liver Imaging Reporting and Data System (LI-RADS) has developed a Treatment Response (LR-TR) algorithm. Introduced in 2017, the system provides criteria to categorize response of HCC to locoregional treatment (e.g., chemical ablation, energy-based ablation, transcatheter therapy, and radiation therapy). LR-TR categories include Nonevaluable, Nonviable, Equivocal, and Viable. LR-TR does not apply to patients on systemic therapies. This article reviews the LR-TR algorithm; discusses locoregional therapies for HCC, treatment concepts, and expected posttreatment findings; and illustrates LI-RADS treatment response assessment with CT and MRI.
AB - Computed tomography (CT) and magnetic resonance imaging (MRI) play critical roles for assessing treatment response of hepatocellular carcinoma (HCC) after locoregional therapy. Interpretation is challenging because posttreatment imaging findings depend on the type of treatment, magnitude of treatment response, time interval after treatment, and other factors. To help radiologists interpret and report treatment response in a clear, simple, and standardized manner, the Liver Imaging Reporting and Data System (LI-RADS) has developed a Treatment Response (LR-TR) algorithm. Introduced in 2017, the system provides criteria to categorize response of HCC to locoregional treatment (e.g., chemical ablation, energy-based ablation, transcatheter therapy, and radiation therapy). LR-TR categories include Nonevaluable, Nonviable, Equivocal, and Viable. LR-TR does not apply to patients on systemic therapies. This article reviews the LR-TR algorithm; discusses locoregional therapies for HCC, treatment concepts, and expected posttreatment findings; and illustrates LI-RADS treatment response assessment with CT and MRI.
KW - Computed tomography
KW - Hepatocellular carcinoma
KW - LI-RADS Treatment Response
KW - LIRADS
KW - Locoregional
KW - Magnetic resonance imaging
UR - http://www.scopus.com/inward/record.url?scp=85076899020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076899020&partnerID=8YFLogxK
U2 - 10.1186/s13244-019-0801-z
DO - 10.1186/s13244-019-0801-z
M3 - Review article
C2 - 31853668
AN - SCOPUS:85076899020
SN - 1869-4101
VL - 10
JO - Insights into Imaging
JF - Insights into Imaging
IS - 1
M1 - 121
ER -